Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

DiaMedica Announces Resignation of Board Member


Print article Print article
© Marketwire 2013
2013-02-23 00:41:37 -

MINNEAPOLIS, MINNESOTA -- (Marketwire) -- 02/22/13 -- DiaMedica (TSX VENTURE:DMA) announces today that David Allan has resigned from the Company's board of directors, effective February 22, 2013.


"On behalf of our board of directors, I thank David for his valuable service and contributions and wish him well in future endeavors," stated Rick Pauls, Chairman & CEO of DiaMedica.



About DiaMedica


DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes. DiaMedica's lead compound, DM-199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications. The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more information please visit www.diamedica.com.


FORWARD-LOOKING STATEMENTS


The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.



Contacts:

DiaMedica Inc.

Rick Pauls

Chairman & CEO

763-710-4455
info@diamedica.com :

www.diamedica.com

at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid= .. width="1" height="1" alt=" " border="0" />



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser